RxDoctor Payments Data

Timothy Meilner, MD

Family Medicine · Cedaredge, CONPI 1467583450

Payments from drug & device makers

$589in general payments, 2019–2025

Across 31 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$267
  • AstraZeneca$126
  • GSK$46
  • Astellas Pharma US Inc$34
  • Axonics, Inc.$33
  • Sanofi Pasteur Inc.$30
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$589100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)13$267
AstraZeneca8$126
GSK2$46
Astellas Pharma US Inc2$34
Axonics, Inc.1$33
Sanofi Pasteur Inc.2$30
Exact Sciences1$21
Amgen1$20
Pfizer1$13

How this compares

$589 in reported general payments places this provider in the 75th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$135,076
Medicare patients
309
Services billed
2,593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine18$207,121
EliquisApixaban159$110,587
Humira(Cf) PenAdalimumab11$77,348
OzempicSemaglutide54$55,396
VraylarCariprazine Hcl11$45,997
XareltoRivaroxaban31$35,602
JardianceEmpagliflozin44$30,830
CreonLipase/Protease/Amylase14$29,220
Nurtec OdtRimegepant Sulfate11$20,914
Combivent RespimatIpratropium/Albuterol Sulfate20$16,020
Breo ElliptaFluticasone/Vilanterol15$11,718
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$10,564
Quetiapine Fumarate125$9,145
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,761
EntrestoSacubitril/Valsartan25$8,581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$13$131,501170 claims
AbbVieVraylar, Creon$267$75,21725 claims
GSKBreo Ellipta, Trelegy Ellipta$46$20,47928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Cedaredge

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →